Scholars Central

Conference abstractPublished 11 Jul 2016

The quest of new cancer models and their properties in the NGS era

Authors: Ugo Rovigatti

University of Florence Medical School, Italy

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

It is today indisputable that great progresses have been made in our molecular understanding of cancer cells but an effective implementation of such knowledge into dramatic cancer-cures is still belated and yet desperately needed. This review gives a snapshot at where we stand today in this search for cancer understanding and definitive treatments, how far we have progressed and what are the major obstacles we will have to overcome both technologically and for disease modeling. In the first part, promising 3rd/4th Generation Sequencing Technologies will be summarized (particularly Ion Torrent and Oxford Nanopore technologies). Cancer modeling will be then reviewed from its origin in XIX Century Germany to todayâÂ?Â?s NGS applications for cancer understanding and therapeutic interventions. Developments after Molecular Biology revolution (1953) are discussed as successions of three phases. The first, PH1, labeled âÂ?Â?Clonal OutgrowthâÂ? (from 1960s to mid 1980s) was characterized by discoveries in cytogenetics (Nowell, Rowley) and viral oncology (Dulbecco, Bishop, Varmus), which demonstrated clonality. Treatments were consequently dominated by a âÂ?Â?cytotoxic eradicationâÂ? strategy with chemotherapeutic agents. In PH2, (from the mid 1980s to our days) the description of cancer as âÂ?Â?Gene NetworksâÂ? led to targeted-gene-therapies (TGTs). TGTs are the focus of Section 3: In view of their apparent failing (Ephemeral Therapies), alternative strategies will be discussed in review part II (particularly cancer immunotherapy (CIT). Additional Pitfalls impinge on the concepts of tumor heterogeneity (inter/intra; ITH). The described pitfalls set the basis for a new phase, PH3, which is called âÂ?Â?NGS EraâÂ? and will be also discussed with ten emerging cancer models in the Review 2nd part..

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Ugo Rovigatti”